Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenues	$ 2,965.1	$ 2,528.7
Ronapreve | Roche Collaboration Agreement | Collaboration revenue
Disaggregation of Revenue [Line Items]
Revenues	$ 216.3	66.8
Reimbursement of research and development expenses | Roche Collaboration Agreement | Research and development expense
Disaggregation of Revenue [Line Items]
Revenues		$ 86.8